Navigation Links
Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer

SEATTLE, April 27, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Carlos V. Paya, MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May 2, 2011, to lead IDC into its next stage of growth. Dr. Paya brings a successful track record and over 25 years of scientific, clinical and executive management experience to IDC.  

Current CEO and co-founder Steven Reed, PhD, will continue to serve on IDC's executive management team and Board of Directors and focus his efforts on scientific and strategic partnerships.  Dr. Reed remarked, "We are fortunate to have someone of Dr. Paya's caliber joining IDC.  We are confident that with his broad expertise, he will contribute to IDC's continued growth and success. Throughout his distinguished career, Dr. Paya has consistently demonstrated exceptional business and leadership acumen in a variety of management roles."

Bruce L.A. Carter, PhD, Chairman of IDC's Board of Directors stated, "Dr. Paya is an intelligent, independent thinker who's passionate about IDC's objective to discover and develop therapeutics that will protect and improve the quality of people's lives. I am excited to be working with him as IDC continues to progress."

"I am honored to join such an accomplished and recognized Board of Directors, executive team, and a first in class scientific organization," said Dr. Paya.  "Moreover, the maturing technologies and scientific platforms contributed by the founders of IDC have the potential to revolutionize how we treat and prevent the huge unmet medical need of chronic viral infections, cancer, and autoimmunity. Delivering these potential breakthrough therapies to patients worldwide is an exciting and unique opportunity."

Dr. Paya joins IDC from Elan Corporation, where he was President and led the Biotechnology commercial, marketing, clinical, research and development teams since 2008.  Dr. Paya joined Elan from Eli Lilly & Company, where he was Vice President, Lilly Research Laboratories, and Global Leader of the Diabetes and Endocrine Platform, responsible for the company's diabetes and endocrine franchise. Prior to his career at Lilly, Dr. Paya had a distinguished academic career at the Mayo Clinic where he was a tenured Professor of Medicine, Immunology and Pathology, and Vice Dean of the Clinical Investigation program.

About Immune Design Corp.

Immune Design Corp. is a privately held, clinical-stage biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms.

Additional information can be found on the company's website at

Contact Media:

Cassie Ostrander 206-826-7901 or

SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present 11 Abstracts on Influenza at 45th Annual National Immunization Conference
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
4. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
5. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
6. Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens
7. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
8. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
9. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
10. MedImmune Focused on Revolutionizing Cancer Care
11. London Genetics and Astrimmune to Collaborate on Cancer Vaccine
Post Your Comments:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):